Changes to antiretroviral drug regimens during integrated TB-HIV treatment: Results of the SAPiT trial

Antiviral Therapy

Volumn 19, Issue 2, 2014, Pages 161-169

  Naidoo, Anushka ^a   Naidoo, Kogieleum ^a   Yende Zuma, Nonhlanhla ^a   Gengiah, Tanuja N ^a   Padayatchi, Nesri ^a   Gray, Andrew L ^a,b   Bamber, Sheila ^a   Nair, Gonasagrie ^a   Karim, Salim S Abdool ^a,b,c  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b UNIVERSITY OF KWAZULU NATAL   (South Africa)

^c Department of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; DIDANOSINE; EFAVIRENZ; ETHAMBUTOL PLUS ISONIAZID PLUS PYRAZINAMIDE PLUS RIFAMPICIN; ISONIAZID PLUS RIFAMPICIN; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; STREPTOMYCIN; TENOFOVIR; TUBERCULOSTATIC AGENT; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; BODY MASS; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HEPATOMEGALY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; INCIDENCE; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; OPEN STUDY; PANCREATITIS; PATIENT ASSESSMENT; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PSYCHOPATHY; RANDOMIZED CONTROLLED TRIAL; RASH; TREATMENT RESPONSE; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; VIRUS HEPATITIS; VIRUS LOAD; COMPLICATION; HIV INFECTIONS; MIDDLE AGED; RISK FACTOR;

ADULT; ANTI-HIV AGENTS; ANTITUBERCULAR AGENTS; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; RISK FACTORS; TUBERCULOSIS;

EID: 84898620408     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2701     Document Type: Article

References (38)

1. World Health Organization.Global Tuberculosis Report. Geneva: World Health Organization 2013. (Updated 23 October 2013. Accessed 27 February 2014.) Available from www.who.int/tb/data
2. Lalloo UG. Efavirenz and nevirapine interactions with rifampicin: resolving the dilemmas? Clin Infect Dis 2009; 48:1760-1762.
3. Breen RA, Smith CJ, Bettinson H, et al. Paradoxical reactions during tuberculosis treatment in patients with and without HIV co-infection. Thorax 2004; 59:704-707.
4. Burman W, Weis S, Vernon A, et al. Frequency, severity and duration of immune reconstitution events in HIVrelated tuberculosis. Int J Tuberc Lung Dis 2007; 11:1282-1289.
5. Abdool Karim SS, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010; 362:697-706.
6. Abdool Karim SS, Naidoo K, Grobler A, et al. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med 2011; 365:1492-1501.
7. Blanc FX, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med 2011; 365:1471-1481.
8. Havlir DV, Kendall MA, Ive P, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med 2011; 365:1482-1491.
9. National Institiute of Allergy and Infectious Diseases. Division of AIDS table for grading the severity of adult and pediatric adverse events. Bethesda, MD: National Institutes of Health 2004. (Updated 25 February 2014. Accessed 27 February 2014.) Available from http://www.niaid.nih.gov/LabsAndResources/resources/DAIDSClinRsrch/Documents/daidsaegradingtable.pdf
10. Marks DJ, Dheda K, Dawson R, Ainslie G, Miller RF. Adverse events to anti-Tuberculosis therapy: influence of HIV and antiretroviral drugs. Int J STD AIDS 2009; 20:339-345.
11. Tansuphasawadikul S, Saito W, Kim J, et al. Outcomes in HIV-infected patients on antiretroviral therapy with tuberculosis. Southeast Asian J Trop Med Public Health 2007; 38:1053-1060.
12. Dean GL, Edwards SG, Ives NJ, et al. Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. AIDS 2002; 16:75-83.
13. Gengiah TN, Gray AL, Naidoo K, Abdool Karim Q. Initiating antiretrovirals during tuberculosis treatment: a drug safety review. Expert Opin Drug Saf 2011; 10:559-574.
14. Westreich DJ, Sanne I, Maskew M, et al. Tuberculosis treatment and risk of stavudine substitution in first-line antiretroviral therapy. Clin Infect Dis 2009; 48:1617-1623.
15. Hoffmann CJ, Charalambous S, Thio CL, et al. Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B. AIDS 2007; 21:1301-1308.
16. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000; 283:74-80.
17. Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 2002; 35:182-189.
18. Bruno R, Sacchi P, Maiocchi L, Zocchetti C, Filice G. Hepatotoxicity and nelfinavir: a meta-Analysis. Clin Gastroenterol Hepatol 2005; 3:482-488.
19. den Brinker M, Wit FW, Wertheim-van Dillen PM, et al. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 2000; 14:2895-2902.
20. Wit FW, Weverling GJ, Weel J, Jurriaans S, Lange JM. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis 2002; 186:23-31.
21. Law WP, Dore GJ, Duncombe CJ, et al. Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001. AIDS 2003; 17:2191-2199.
22. Dieleman JP, Jambroes M, Gyssens IC, et al. Determinants of recurrent toxicity-driven switches of highly active antiretroviral therapy. The ATHENA cohort. AIDS 2002; 16:737-745.
23. Lodenyo H, Schoub B, Ally R, Kairu S, Segal O. Hepatitis B and C virus infections and liver function in AIDS patients at Chris Hani Baragwanath Hospital, Johannesburg. East Afr Med J 2000; 77:13-15.
24. Matee MI, Magesa PM, Lyamuya EF. Seroprevalence of human immunodeficiency virus, hepatitis B and C viruses and syphilis infections among blood donors at the Muhimbili National Hospital in Dar es Salaam, Tanzania. BMC Public Health 2006; 6:21.
25. van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004; 363:1253-1263.
26. Manosuthi W, Kiertiburanakul S, Sungkanuparph S, et al. Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIVinfected patients with tuberculosis receiving rifampicin: 48 weeks results. AIDS 2006; 20:131-132.
27. Gengiah TN, Holford NH, Botha JH, et al. The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis. Eur J Clin Pharmacol 2012; 68:689-695.
28. Antiretroviral therapy for HIV infection in adults and adolecents: recommendations for a public health approach: 2010 revision. Geneva: World Health Organization 2010.
29. Barth RE, van der Loeff MF, Schuurman R, Hoepelman AI, Wensing AM. Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. Lancet Infect Dis 2010; 10:155-166.
30. van Leth F, Andrews S, Grinsztejn B, et al. The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART. AIDS 2005; 19:463-471.
31. Robbins GK, Johnson KL, Chang Y, et al. Predicting virologic failure in an HIV clinic. Clin Infect Dis 2010; 50:779-786.
32. Khienprasit N, Chaiwarith R, Sirisanthana T, Supparatpinyo K. Incidence and risk factors of antiretroviral treatment failure in treatment-naive HIV-infected patients at Chiang Mai University Hospital, Thailand. AIDS Res Ther 2011; 8:42.
33. Fox MP, Cutsem GV, Giddy J, et al. Rates and predictors of failure of first-line antiretroviral therapy and switch to second-line ART in South Africa. J Acquir Immune Defic Syndr 2012; 60:428-437.
34. Colebunders R, Moses KR, Laurence J, et al. A new model to monitor the virological efficacy of antiretroviral treatment in resource-poor countries. Lancet Infect Dis 2006; 6:53-59.
35. Ahoua L, Guenther G, Pinoges L, et al. Risk factors for virological failure and subtherapeutic antiretroviral drug concentrations in HIV-positive adults treated in rural northwestern Uganda. BMC Infect Dis 2009; 9:81.
36. Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006; 367:817-824.
37. Best BM, Goicoechea M, Witt MD, et al. A randomized controlled trial of therapeutic drug monitoring in treatmentnaive and -experienced HIV-1-infected patients. J Acquir Immune Defic Syndr 2007; 46:433-442.
38. van Griensven J, Zachariah R. Increased baseline body weight is a risk factor associated with virological failure while on antiretroviral treatment. J Acquir Immune Defic Syndr 2008; 48:631-633.